期刊文献+

人脑胶质瘤中神经生长因子表达与组织病理分级及预后的关系 被引量:4

Expression of nerve growth factor in glioma and the relationship with the pathological grade and prognosis
原文传递
导出
摘要 目的探讨人脑胶质瘤中神经生长因子(nerve growth factor,NGF)的表达特点,了解其与肿瘤组织病理分级及预后间的相关性。方法观察86例脑胶质瘤患者脑胶质瘤组织及10例脑外伤行内减压术患者正常脑组织中NGF表达情况,并分析NGF核阳性率与脑胶质瘤病理分级及预后的关系。结果 NGF在正常脑组织中主要分布于细胞质,而在胶质瘤组织中分布于细胞质及细胞核中;高级别胶质瘤组NGF核阳性率(69.0%)高于低级别组(32.2%)(P<0.05);胶质瘤中NGF表达阳性者中位生存时间低于阴性者(P<0.05)。结论 NGF在脑胶质瘤中水平变化与胶质瘤组织病理分级、预后密切相关。 Objective To study the expression of nerve growth factor (NGF) in glioma and the relationship with the pathological grade and prognosis. Methods The expression of NGF was detected with immuno-histochemical method in 86 patients with glioma and 10 brain trauma patients receiving decompression surgery. The relationship of NGF nuclear positive rate with pathological grade and prognosis was analyzed. Results NGF-positive immunoreactive products were distributed in both cytoplasm and nucleus of glioma, but were only located in cytoplasm of traumatic brain injury tissue. NGF nuclear-positive rate (NPR) of grades III to IV gliomas (69.0%) was higher than that of grades I to U gliomas (32.2%) (P〈0.05). The median survival time was longer in positive NGF glioma patients than that in negative NGF glioma patients (P〈0.05). Conclusion The expression of NGF is closely correlated with the pathological grade and prognosis, and may participate in the tumorigenesis of glioma.
出处 《中华实用诊断与治疗杂志》 2012年第10期958-960,共3页 Journal of Chinese Practical Diagnosis and Therapy
基金 江苏省自然科学基金项目(BK2008235)
关键词 胶质瘤 神经生长因子 病理分级 预后 Glioma nerve growth factor pathological grade prognosis
  • 相关文献

参考文献8

二级参考文献94

共引文献41

同被引文献25

  • 1付浩,孙开来.B—RAF基因和肿瘤[J].国际遗传学杂志,2007,30(3):198-201. 被引量:2
  • 2Liu S, Yin F, Fan W, et al. Over-expression of BMPR- IB reduces the malignancy of glioblastoma cells by upregulation of p21 and p27Kip1[J]. J Exp Clin Cancer Rcs,2012,31:52.
  • 3Liu S, Tian Z, Yin F, et al. Expression and functional roles of Smad1/5/8 and BMPR-IB in glioma development[J]. Cancer Invest,2009,27(7) :734-740.
  • 4Peterson K. Brain tumors[J]. Neurol Clin, 2001,19 (4) : 887 902.
  • 5Wistuba Ⅱ, Gelovani JG, Jacoby JJ, et al. Methodological and practical challenges for personalized cancer therapies[J]. Nat Rev Clin Oncol,2011,8(3):135 141.
  • 6Weller M, Wick W, Hegi ME, et al. Should biomarkers be used to design personalized medicine for the treatment of glioblastoma [J]. Future Oncol, 2010,6 (9) : 1407-1414.
  • 7Torres J, Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus: implications PTEN stability to proteasome-mediated degradation [J]. J Biol Chem,2001,276(2) ,993-998.
  • 8Gass D,Dewire M,Chow L,et al.Pediatric tectal plate gliomas:a review of clinical outcomes,endocrinopathies,and neuropsychological sequelae[J].J Eurooncol,2015;122(1):169-77.
  • 9Ito H,Fujita K,Tagawa K,et al.HMGB1facilitates repair of mitochondrial DNA damage and extends the lifespan of mutant ataxin-1knock-in mice[J].EMBO Mol Med,2014;7(1):78-101.
  • 10Joel M,Mughal AA,Grieg Z,et al.Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo[J].Mol Cancer,2015;14:121.

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部